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S U M M A R Y
Objectives: Antiretroviral therapy (ART) reduces the morbidity and mortality of patients infected with
HIV. Standard ART includes either nevirapine or efavirenz, however the efﬁcacy of these drugs is limited
in patients receiving rifampin treatment for tuberculosis (TB). We compared the efﬁcacy and safety of
nevirapine- and efavirenz-based ART regimens in patients co-infected with both HIV and TB through a
systematic review and meta-analysis.
Methods: A comprehensive search of the literature was carried out to identify clinical trials comparing
the efﬁcacy and safety of nevirapine- and efavirenz-based ART regimens in HIV-associated TB. Eligible
clinical studies included at least one primary or secondary event; the primary event was virological
response and secondary events were TB treatment outcomes, mortality, and safety proﬁle.
Results: This meta-analysis compared ﬁve randomized clinical trials and four retrospective clinical trials.
Both included patients co-infected with HIV and TB; 833 received nevirapine, while 1424 received
efavirenz. The proportion of patients achieving a virological response by the end of the follow-up was
higher in the efavirenz group: plasma viral load <400 copies/ml, risk ratio (RR) 1.10, 95% conﬁdence
interval (CI) 1.03–1.17 (p = 0.004); plasma viral load<50 copies/ml, RR 1.07, 95% CI 0.98–1.16 (p = 0.146).
No signiﬁcant differences were found in either mortality (RR 0.70, 95% CI 0.44–1.13, p = 0.142) or TB
treatment outcomes (RR 1.01, 95% CI 0.96–1.06, p = 0.766). Due to adverse advents, nevirapine-based
regimens signiﬁcantly increased the risk of discontinuation of assigned ART (RR 0.43, 95% CI 0.23–0.81, p
= 0.009).
Conclusions: Although efavirenz-based ART was associated with more satisfactory virological outcomes,
nevirapine-based ART could be considered an acceptable alternative for patients for whom efavirenz
cannot be administered.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The advent of highly active antiretroviral therapy (ART) has
greatly reduced both the mortality and morbidity caused by HIV.1
Among HIV-infected individuals, tuberculosis (TB) has emerged as
one of the most frequent opportunistic infections, and is a leading
cause of death in resource-limited areas.2 Although both ART and
anti-TB therapy (ATT) have been shown to improve survival in* Corresponding author. Fax: +86 57187236585.
E-mail address: hzruanbing@gmail.com (B. Ruan).
1 Both authors contributed equally to this work.
http://dx.doi.org/10.1016/j.ijid.2014.04.020
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).co-infected patients, the use of certain ART regimens remains
controversial due to concerns over adverse drug interactions.
Nevirapine and efavirenz, two classes of non-nucleoside reverse
transcriptase inhibitor (NNRTI), are recommended as ﬁrst-line ART
regimens in resource-limited settings.3 Rifampin, a key component
of ATT, is a potent inducer of the cytochrome P450 enzyme system;
activation of this system leads to enhanced clearance of NNRTIs.4,5
Efavirenz is recommended by the World Health Organization
(WHO) for patients infected with HIV and TB due to a lower risk of
sub-therapeutic concentration than nevirapine or protease inhi-
bitors (PIs).6 The preferred antiretroviral regimen for co-adminis-
tration with rifampin is two nucleoside reverse transcriptase
inhibitors plus efavirenz, however, nevirapine is more widely usedciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Figure 1. Flow chart of study selection.
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food restrictions, and more convenient dosing. Moreover, nevirapine
is effective for preventing mother-to-child transmission of HIV.7
Although several randomized trials have been conducted to
compare the efﬁcacies of nevirapine- and efavirenz-based regi-
mens, the use of these drugs remains controversial. Due to
differences in methodology, including retrospective designs, non-
randomized designs, small sample sizes, and differences in the
criteria used for scaling adverse events, deﬁnitive conclusions
remain elusive. To address these issues, we performed a systematic
review and meta-analysis of the existing data to compare the
efﬁcacy and safety of nevirapine- to efavirenz-based ART when
administered with rifampin-based ATT.
2. Methods
2.1. Literature search
We searched the medical literature published between January
1990 and February 2014 using PubMed, Embase, and the Cochrane
Database. We conducted the search using the terms ‘efavirenz’,
‘nevirapine’, and ‘rifampin or tuberculosis or TB’. In addition, we
examined the bibliographies of reviews, original studies, and relevant
conference articles, and directly contacted some investigators.
2.2. Inclusion and exclusion criteria
Criteria for inclusion were: (1) study design was a randomized
controlled trial (RCT) or cohort study; (2) study subjects were HIV
patients presenting with concomitant TB; (3) two study arms
included standard doses of nevirapine- versus efavirenz-based
ART; and (4) the ATT was rifampin-based.
The primary outcome was the virological response at the end of
follow-up. Plasma viral load (pVL) is a globally accepted endpoint
used to measure the efﬁcacy of ART. Available data on the
virological response in the studies included were recorded as a
plasma HIV RNA level <50 and <400 copies/ml. It should be noted
that suppression of pVL to 50 copies/ml is a better generalized
predictor of durable virological success.8,9 The secondary out-
comes were mortality, TB treatment, and safety proﬁle (risk of
adverse events and discontinuation of the study because of adverse
events). TB treatment outcomes were deﬁned as per the WHO
guidelines.10 Studies including at least one primary or secondary
event were eligible for the analysis. Studies published in a language
other than English were not included, nor were articles published
as comments, reviews, or editorials. Data from the same trial were
skimmed for relevant information.
2.3. Quality assessment and data extraction
Two authors independently assessed the methodological
quality of the selected studies. To assess the methodological
quality of the included RCTs we used the Cochrane risk of bias
assessment tool. For observational studies we used the Newcastle–
Ottawa quality assessment scale. All relevant information was
collected, including patient demographics, year of publication,
study location, study design, characteristics of the study popula-
tion (age, gender, baseline viral load, and CD4 cell count), ART and
ATT regimens, and follow-up time. To ensure accuracy, two
authors working independently extracted the target data.
2.4. Statistical analysis
Relative risks (RR) with 95% conﬁdence intervals (CI) were used
to estimate the strength of association between dichotomous
variables. Patients lost to follow-up in retrospective studies werenot included in our virological analysis. For RCTs, the RR for
primary and secondary outcomes were calculated on an intention-
to-treat basis. We assessed heterogeneity using the Chi-square-
based Q-test, with I2 as a measure of inconsistency; a random-
effects model was used for comparisons exhibiting a Q-test p value
of <0.10 or I2 > 50%.11,12 A subgroup analysis of RCTs and non-
randomized controlled trials (nonRCTs) was carried out to identify
differences between the two study types and verify the accuracy of
our results. Where sufﬁcient studies were available, publication
bias was assessed visually using funnel plots.13 All of the above
analyses were conducted using Stata 11.0 software (StataCorp LP,
College Station, TX, USA).
3. Results
3.1. Search results
Following a search of three databases and the bibliographies of
relevant publications, a total of 802 potentially eligible articles
were identiﬁed. Fifty-six duplicate articles were excluded from the
analysis, along with 718 articles deemed irrelevant after reading
the title and abstract. The remaining 28 potentially relevant papers
were examined thoroughly. Articles were excluded based on the
inclusion criteria listed in the Methods section, resulting in a total
of 11 publications referring to nine trials.14–24 A ﬂow diagram of
the literature search and selection process is given in Figure 1.
3.2. Characteristics of the studies included
The characteristics of the nine studies considered in this
analysis are presented in Table 1. Four studies16,21,22,24 were
conducted in Asia, four17–19,23 in Africa, and one20 in Spain. The
total number of patients was 2257. The mean age of participants
ranged from 32 to 38 years, and the proportion of male participants
ranged from 24% to 85%. The duration of ART was 24 to 96 weeks.
The sample size varied from 33 to 849 patients.
All trials involved patients co-infected with both HIV and TB.
Mean baseline viral loads ranged from 5.3 to 5.7 copies/ml, and
mean baseline CD4 cell counts ranged from 36 to 139 cells/ml. Most
trials included patients with pulmonary TB, all of whom received
rifampin-containing anti-TB regimens. The patients in one study21
initiated nevirapine at the full dose (400 mg/day) without the 2-
week lead in dose (200 mg) in order to limit the risk of sub-
therapeutic nevirapine concentrations during the initiation of
treatment. Thirty patients in one study,20 treated with 800 mg
efavirenz daily, were excluded from our analysis.
Table 1
Characteristics of included studies
Study Location Design Sample
size
Male
%
Viral load,
copies/ml
CD4 cell
count,
cells/ml
Pulmonary
TB %
Rifampin
dose
Intervention Follow-up,
months
Arm 1 Arm 2
Manosuthi
et al., 2009
Thailand RCT Arm 1, n = 71
Arm 2, n = 71
64.8
69.0
5.57
5.57
74.8
55.8
63.4
57.7
450–600
mg/day
3TC+d4T+NVP 3TC+d4T+EFV 48
Swaminathan
et al., 2011
India RCT Arm 1, n = 57
Arm 2, n = 59
83
77
5.55
5.45
85
83
73
65
450–600
mg/day
3TC+ddI+NVP 3TC+ddI+EFV 24
Matteelli
et al., 2013
Burkina Faso RCT Arm 1, n = 33
Arm 2, n = 36
NR NR NR NR NR 3TC+d4T+NVP 3TC+d4T+EFV 48
Bonnet
et al., 2013
Mozambique RCT Arm 1, n = 285
Arm 2, n = 285
60
56
5.5
5.7
86
95
76
79
10 mg/kg 3TC+d4T+NVP 3TC+d4T+EFV 48
Sinha
et al., 2013
India RCT Arm 1, n = 67
Arm 2, n = 68
79.1
59
5.52
5.19
137
139
23.9
27.9
NR AZT+3TC+NVP AZT+3TC+EFV 96
Boulle
et al., 2008
South Africa RC Arm 1, n = 141
Arm 2, n = 708
37.9
26.3
5.3
5.3
61
80
62.8
62.7
NR 2NRTI+NVP 2NRTI+EFV 72
Manosuthi
et al., 2008
Thailand RC Arm 1, n = 111
Arm 2, n = 77
54
82
5.6
5.7
36
36
44
50
NR NVP-based regimen EFV-based regimen 48
Shipton
et al., 2009
Botswana RC Arm 1, n = 55
Arm 2, n = 100
NR NR 54
61
NR NR AZT+3TC+NVP AZT+3TC+EFV 48
Villar
et al., 2009
Spain RC Arm 1, n = 13
Arm 2, n = 20
84.5 5.3 86 NR NR NVP-based regimen EFV-based regimen 48
RCT, randomized controlled trial; RC, retrospective controlled; 3TC, lamivudine; d4T, stavudine; NVP, nevirapine; EFV, efavirenz; ddI, didanosine; AZT, zidovudine; NRTI,
nucleoside reverse transcriptase inhibitor; NR, not reported.
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3.3.1. Virological response
Seven studies reported the number of patients achieving a
virological response at the end of follow-up, i.e., plasma viral load
<400 copies/ml. Based on Chi-square and I2 analyses (Chi-square =
5.46, p = 0.486; I2 = 0%), a ﬁxed-effect approach was used to
estimate the RR of efavirenz vs. nevirapine. The pooled data
demonstrated a statistically different rate of virological response inFigure 2. Comparison of the efavirenz and nevirapine groups by virothe efavirenz group compared to the nevirapine group (RR 1.10,
95% CI 1.03–1.17, p = 0.004); this result was consistent with that of
the nonRCT subgroup analysis (RCTs: RR 1.09, 95% CI 1.01–1.19, p =
0.038; nonRCTs: RR 1.11, 95% CI 1.01–1.21, p = 0.032) (Figure 2).
We also evaluated the virological response in terms of plasma
viral loads <50 copies/ml at the end of follow-up. Although the
result was not signiﬁcantly different at the end of follow-up, there
was a trend towards an increase in virological response in patients in
the efavirenz group (RR 1.07, 95% CI 0.98–1.16, p = 0.146) (Figure 3).logical response (pVL <400 copies/ml) at the end of follow-up.
Figure 3. Comparison of the efavirenz and nevirapine groups by virological response (pVL <50 copies/ml) at the end of follow-up.
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An analysis of 824 patients from three studies revealed no
signiﬁcant difference in patients who achieved a favorable
response to anti-TB treatment (RR 1.01, 95% CI 0.96–1.06, p =
0.766), with modest heterogeneity (Chi-square = 2.42, p = 0.299;
I2 = 17.2%) in each group (Figure 4).Figure 4. Comparison of the efavirenz and nevirapine groups by TB treatm3.3.3. Mortality
To reduce the heterogeneity of the data, only RCTs were
included in our evaluation of mortality. Heterogeneity was
assessed using an I2 analysis, with no signiﬁcant difference
evident (Chi-square = 4.22, p = 0.239; I2 = 28.9%). A ﬁxed-effect
approach was used to estimate the effects of efavirenz vs.ent outcome, mortality, and discontinuation due to adverse events.
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identify a statistically signiﬁcant difference between the two
groups (RR 0.70, 95% CI 0.44–1.13, p = 0.142) (Figure 4). The most
common cause of death was severe infection; no deaths were
attributed to either of the study drugs.
3.3.4. Safety proﬁle
No signiﬁcant heterogeneity in the rate of discontinuation of
ART was observed between studies (Chi-square = 4.01, p = 0.26; I2 =
25.2%). However, a meta-analysis revealed a higher risk of
treatment discontinuation due to adverse events in the nevirapine
group (RR 0.43 95% CI 0.23–0.81, p = 0.009) (Figure 4).
The most common causes for withdrawal of ART were hepatitis,
skin rash, and psychiatric disorders. Three cases of Stevens–
Johnson syndrome were reported, but these were resolved after
discontinuation of nevirapine or switching to efavirenz. Three
cases of clinically important psychiatric disorders were reported in
the efavirenz group. Neurological, gastrointestinal, and cutaneous
adverse events were the most common side effects reported in four
studies.
4. Discussion
To our knowledge, this systematic review is the ﬁrst to compare
the efﬁcacy and safety of standard doses of nevirapine and
efavirenz in patients co-infected with HIV and TB only. The present
review suggests that ART regimens containing efavirenz used in
association with rifampin were associated with a more successful
virological response than nevirapine; these ﬁndings were consis-
tent across the study design. Our results suggest that ART that
includes efavirenz (600 mg per day) should be preferred over that
which contains nevirapine (400 mg per day) for eligible patients
co-infected with HIV and TB.
A Cochrane review of seven randomized clinical trials
demonstrated that the two drugs provided comparable levels of
viral suppression in non-TB patients infected with HIV when
combined with two nucleoside reverse transcriptase inhibitors
(NRTIs).25 In our meta-analysis, patients in the efavirenz treatment
group achieved statistically higher rates of virological response,
likely due to the effects of rifampin on drug metabolism.26
Rifampin is a potent inducer of the cytochrome P450 enzymes,
which metabolize many drugs, including NNRTI antiretroviral
agents.5,27 These effects are not uniform across NNRTIs, as the
current data clearly show a more signiﬁcant reduction in plasma
nevirapine concentrations when using standard methods of
administration and in standard doses, compared to efavirenz.
Therefore, standard nevirapine-based regimens pose a greater risk
of sub-therapeutic NNRTI concentrations in patients co-infected
with TB. In order to limit the risk of sub-therapeutic nevirapine
concentrations during the initiation of treatment,28,29 nevirapine
at full doses (400 mg/day) without a 2-week lead in dose was given
in the trial conducted by Bonnet et al. In a pharmacokinetic study, a
median minimum concentration of plasma nevirapine was
observed that was higher than the minimum therapeutic
concentration of 3 mg/l.30 However, the clinical effect was not
conﬁrmed. A more recent meta-analysis concluded that even in
non-HIV–TB co-infected patients, the efavirenz-based regimen is
less likely to lead to virological failure compared to nevirapine.31
Therefore, in HIV–TB co-infected patients, even if the lower
virological response with nevirapine is likely to be explained by the
stronger induction of nevirapine by rifampin, we could not exclude
that part of the reason is also potentially due to the lower intrinsic
potency of nevirapine compared to efavirenz. Hence, there is
insufﬁcient evidence to recommend a higher dose of nevirapine for
patients on rifampin at this time.32To minimize the heterogeneity of the data, we further
conducted a meta-analysis based on the type of study (RCT or
nonRCT), and found that the type of study did not affect the overall
conclusions. Our conclusions regarding the virological response in
the two treatment groups are consistent with those of Bonnet
et al.19 and Boulle et al.,23 whose results had relatively high
statistical power with a large sample size. Both studies suggested
that nevirapine-based regimens were less effective than efavir-
enz-based regimens. Furthermore, differences in virological
measurements may be a potential source of heterogeneity.
Therefore, we conducted our meta-analyses based on consistent
virological measurements. Using this standardized approach, the
same trends were found in the efavirenz treatment groups across
multiple trials.
Another important issue is the outcome of ATT. The overall rates
of favorable response to ATT were comparable between studies,
with no signiﬁcant differences between groups. A rifampin-
containing regimen has been recommended by the WHO for the
treatment of TB in patients infected with HIV due to its more
favorable outcomes than non-rifampin treatments.33 ART is also
important for the treatment of TB, as viral suppression is necessary
for the restoration of Mycobacterium tuberculosis-speciﬁc CD4+ T
cell responses.34 Accordingly, a combination of ATT and ART has
been shown to reduce both the morbidity and mortality associated
with HIV-associated TB.35 One important caveat, however, is the
occurrence of immune reconstitution inﬂammatory syndrome,
which occurs frequently in HIV-infected patients receiving both
ATT and ART.
Regarding the safety proﬁle, our meta-analysis favored
efavirenz, as the frequent occurrence of hepatotoxicity and skin
reactions contributed to signiﬁcantly higher rates of discontinua-
tion due to adverse advents in the nevirapine group. However, the
overall toxicity proﬁles of nevirapine and efavirenz were
comparable. It should be noted that efavirenz has been linked
with a higher risk of central nervous system side effects, while
nevirapine has been found to be a safe therapeutic option for
patients at risk of psychiatric disorders.36
Our results need to be interpreted with caution due to several
limitations. First, the number of eligible studies was small. This
resulted in a lack of data for some confounding factors, which may
have inﬂuenced the accuracy of the results. Differences in lengths
of follow-up and the analyzed endpoint deﬁnitions were potential
sources of heterogeneity for the included studies. Second, several
of the available studies had limited power, owing to small sample
sizes and high withdrawal rates. Third, due to the limited number
of published studies, we expanded the search to include nonRCTs
and four retrospective studies in our meta-analysis. The risk of bias
in these types of study is high, further diminishing the statistical
power of the analyses. While these limitations are important to
consider, such problems are inherent to the nature of meta-
analyses, as they are based on secondary analyses of primary
research.
In conclusion, the results of this meta-analysis indicate that the
efavirenz regimen for patients co-infected with HIV and TB is
associated with more successful virological outcomes compared to
a standard nevirapine regimen. Therefore, it may be advisable to
choose efavirenz-based ART when co-administered along with a
rifampin-based anti-TB therapy. However, nevirapine-based ART
could be considered an acceptable alternative in situations where
efavirenz cannot be administered. Accordingly, the best treatment
strategy for this group of patients still involves a considerable
degree of clinical judgment.
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